On March 31, 2020, Grifols, S.A., a company listed on the NASDAQ and Bolsa de Madrid , acquired 26.2% of the equities of Shanghai RAAS Blood Products Co., Ltd., an A-share listed company, and the corresponding shares are listed on the Shenzhen Stock Exchange, completing the final closing of Grifols’ strategic investment in Shanghai RAAS by way of cross-border equity swaps.